Compare Johnson & Johnson (JNJ) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Levi Strauss & Co. — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Levi Strauss & Co. trades at $18.7 (market cap $7.31B). The key difference: Johnson & Johnson is far larger — about 84.6× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Levi Strauss & Co. for 70 Days on average.
| JNJ | LEVI | |
|---|---|---|
Market Cap | $618.09B | $7.31B |
Volume | 6,050,983 | 13,683,095 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $25.53 |
52-Week Low | $186.00 | $17.92 |
Typical Hold Time | 129 Days | 70 Days |
Enterprise Value | $646.37B | $8.86B |
Dividend Yield | 2.09% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Levi Strauss (LEVI) trades at $19.05, down 2.36% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for four consecutive quarters, with Q3 2026 EPS of $0.48 exceeding expectations. Valuation metrics appear attractive with a P/E of 12.53 and P/S of 1.12, while profitability remains solid with a net income margin of 8.83% and ROE of 25.76%.
Wall Street maintains a bullish stance with 15 buy ratings and a consensus price target of $29.00, implying significant upside. However, technical indicators show bearish momentum, and risks include competitive pressures and recent cybersecurity incidents. The stock's current price near recent support levels presents a potential entry point for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
